Heat Shock Protein-Based Cancer Vaccines

Hematology/Oncology Clinics of North America

Volumn 20, Issue 3, 2006, Pages 637-659

  Lee, Kelvin P ^a   Raez, Luis E ^a   Podack, Eckhard R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIINFECTIVE AGENT; BORTEZOMIB; CANCER VACCINE; CHAPERONE; GLYCOPROTEIN GP 96; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; IMATINIB; INTERFERON; MEASLES VACCINE; PROTEASOME INHIBITOR; SYNTHETIC PEPTIDE; TUMOR ANTIGEN; TUMOR VACCINE;

ABDOMINAL PAIN; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPLEX FORMATION; DIARRHEA; DRUG FORMULATION; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; HYPERTHERMIA; IMMUNOTHERAPY; IN VIVO STUDY; INFORMATION; INJECTION SITE ABSCESS; KIDNEY FAILURE; MALAISE; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PRIORITY JOURNAL; PRURITUS; PURIFICATION; REVIEW; SKIN INDURATION; T LYMPHOCYTE; VERTIGO; VOMITING;

ANTIGEN-PRESENTING CELLS; CANCER VACCINES; HEAT-SHOCK PROTEINS; HUMANS; IMMUNE SYSTEM;

EID: 33744528830     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.02.007     Document Type: Review

References (140)

1. Harris G. New drug points up problems in developing cancer cures. New York Times (December 21, 2005)
2. Achievements in public health, 1900-1999 impact of vaccines universally recommended for children-United States, 1900-1998. MMWR Mortal Morbid Wkly Rep 48 (1999) 243-248
3. Srivastava P.K. Immunotherapy of human cancer: lessons from mice. Nat Immunol 1 (2000) 363-366
4. Stone R.M., O'Donnell M.R., and Sekeres M.A. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) (2004) 98-117
5. Arya M., Chao D., and Patel H.R. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer. Nat Clin Pract Oncol 1 (2004) 32-38
6. Hsu F.J., Caspar C.B., Czerwinski D., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89 (1997) 3129-3135
7. Bergenbrant S., Yi Q., Osterborg A., et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 92 (1996) 840-846
8. Marshall J.L., Hawkins M.J., Tsang K.Y., et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 17 (1999) 332-337
9. Thurner B., Haendle I., Roder C., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190 (1999) 1669-1678
10. Jager E., Gnjatic S., Nagata Y., et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 97 (2000) 12198-12203
11. Rasmussen T., Hansson L., Osterborg A., Johnsen H.E., and Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 101 (2003) 4607-4610
12. Massaia M., Borrione P., Battaglio S., et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94 (1999) 673-683
13. Osterborg A., Yi Q., Henriksson L., et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 91 (1998) 2459-2466
14. Yee C., Thompson J.A., Byrd D., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99 (2002) 16168-16173
15. Malmberg K.J. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?. Cancer Immunol Immunother 53 (2004) 879-892
16. Knutson K.L., Schiffman K., Cheever M.A., and Disis M.L. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8 (2002) 1014-1018
17. Dhodapkar M.V., Geller M.D., Chang D.H., et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197 (2003) 1667-1676
18. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148
19. Corthay A., Skovseth D.K., Lundin K.U., et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 22 (2005) 371-383
20. Ikeda H., Chamoto K., Tsuji T., et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95 (2004) 697-703
21. Mesa C., and Fernandez L.E. Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol 82 (2004) 644-650
22. Hawiger D., Inaba K., Dorsett Y., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194 (2001) 769-779
23. Steinman R.M., and Nussenzweig M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 99 (2002) 351-358
24. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199 (2004) 227-250
25. Mellman I., and Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106 (2001) 255-258
26. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
27. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
28. Fernandez N.C., Lozier A., Flament C., et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5 (1999) 405-411
29. Kharfan-Dabaja M.A., Ayala E., Lindner I., et al. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol Immunother 54 (2005) 25-36
30. Bonifaz L., Bonnyay D., Mahnke K., et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196 (2002) 1627-1638
31. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 12 (1994) 991-1045
32. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
33. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 (2002) 709-760
34. Guermonprez P., and Amigorena S. Pathways for antigen cross presentation. Springer Semin Immunopathol 26 (2005) 257-271
35. Ackerman A.L., Kyritsis C., Tampe R., and Cresswell P. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat Immunol 6 (2005) 107-113
36. Guermonprez P., Saveanu L., Kleijmeer M., et al. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425 (2003) 397-402
37. Delamarre L., Holcombe H., and Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 198 (2003) 111-122
38. Nagata Y., Ono S., Matsuo M., et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci U S A 99 (2002) 10629-10634
39. Regnault A., Lankar D., Lacabanne V., et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189 (1999) 371-380
40. Gabrilovich D.I., Chen H.L., Girgis K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [published erratum appears in Nat Med 1996;2(11):1267]. Nat Med 2 (1996) 1096-1103
41. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4 (2004) 941-952
42. Gabrilovich D.I., Corak J., Ciernik I.F., et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3 (1997) 483-490
43. Lee K.P., Harlan D.M., and June C.H. Role of co-stimulation in the host response to infection. In: Gallin J.I., and Synderman R. (Eds). Inflammation: basic principles and clinical correlates (1999), Lippincott Williams & Wilkins, Philadelphia 191-206
44. Liebowitz D.N., Lee K.P., and June C.H. Costimulatory approaches to adoptive immunotherapy. Curr Opin Oncol 10 (1998) 533-541
45. Horspool J.H., Perrin P.J., Woodcock J.B., et al. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J Immunol 160 (1998) 2706-2714
46. Raez L.E., Cassileth P.A., Schlesselman J.J., et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 2800-2807
47. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 13 (1970) 1-27
48. Shankaran V., Ikeda H., Bruce A.T., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
49. Dunn G.P., Bruce A.T., Sheehan K.C., et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 6 (2005) 722-729
50. Willimsky G., and Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005) 141-146
51. Bluestone J.A., and Tang Q. How do CD4+ CD25+ regulatory T cells control autoimmunity?. Curr Opin Immunol 17 (2005) 638-642
52. Nomura T., and Sakaguchi S. Naturally arising CD25+ CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Immunol 293 (2005) 287-302
53. Thompson C., and Powrie F. Regulatory T cells. Curr Opin Pharmacol 4 (2004) 408-414
54. Yu P., Lee Y., Liu W., et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201 (2005) 779-791
55. Schwab S.R., Li K.C., Kang C., et al. Constitutive display of cryptic translation products by MHC class I molecules. Science 301 (2003) 1367-1371
56. Ritossa F. Discovery of the heat shock response. Cell Stress Chaperones 1 (1996) 97-98
57. Macario A.J., and Conway D.M. Sick chaperones, cellular stress, and disease. N Engl J Med 353 (2005) 1489-1501
58. Gullo C.A., and Teoh G. Heat shock proteins: to present or not, that is the question. Immunol Lett 94 (2004) 1-10
59. Schroder M., and Kaufman R.J. The mammalian unfolded protein response. Annu Rev Biochem 74 (2005) 739-789
60. Brewer J.W., and Hendershot L.M. Building an antibody factory: a job for the unfolded protein response. Nat Immunol 6 (2005) 23-29
61. Ma Y., and Hendershot L.M. The role of the unfolded protein response in tumour development: friend or foe?. Nat Rev Cancer 4 (2004) 966-977
62. Obeng E.A., Carlson L.M., Gutman D.M., et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood (2006) in press
63. Meacham G.C., Patterson C., Zhang W., et al. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol 3 (2001) 100-105
64. Connell P., Ballinger C.A., Jiang J., et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3 (2001) 93-96
65. Breloer M., Marti T., Fleischer B., et al. Isolation of processed, H-2Kb-binding ovalbumin-derived peptides associated with the stress proteins HSP70 and gp96. Eur J Immunol 28 (1998) 1016-1021
66. Fourie A.M., Sambrook J.F., and Gething M.J. Common and divergent peptide binding specificities of hsp70 molecular chaperones. J Biol Chem 269 (1994) 30470-30478
67. Chen D., and Androlewicz M.J. Heat shock protein 70 moderately enhances peptide binding and transport by the transporter associated with antigen processing. Immunol Lett 75 (2001) 143-148
68. Calderwood S.K., Theriault J.R., and Gong J. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol 35 (2005) 2518-2527
69. Lammert E., Arnold D., Nijenhuis M., et al. The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur J Immunol 27 (1997) 923-927
70. Nieland T.J., Tan M.C., Monne-van Muijen M., et al. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc Natl Acad Sci U S A 93 (1996) 6135-6139
71. Panjwani N., Akbari O., Garcia S., et al. The HSC73 molecular chaperone: involvement in MHC class II antigen presentation. J Immunol 163 (1999) 1936-1942
72. Zhou D., Li P., Lin Y., et al. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity 22 (2005) 571-581
73. Udono H., and Srivastava P.K. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 178 (1993) 1391-1396
74. Li Z., and Srivastava P.K. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J 12 (1993) 3143-3151
75. Srivastava P.K., and Maki R.G. Stress-induced proteins in immune response to cancer. Curr Top Microbiol Immunol 167 (1991) 109-123
76. Zitvogel L., Regnault A., Lozier A., et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4 (1998) 594-600
77. Thery C., Regnault A., Garin J., et al. Molecular characterization of dendritic cell-derived exosomes: selective accumulation of the heat shock protein hsc73. J Cell Biol 147 (1999) 599-610
78. Wang X.Y., Chen X., Manjili M.H., et al. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100. Cancer Res 63 (2003) 2553-2560
79. Manjili M.H., Henderson R., Wang X.Y., et al. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res 62 (2002) 1737-1742
80. Blachere N.E., Li Z., Chandawarkar R.Y., et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 186 (1997) 1315-1322
81. Oizumi, Podack, in press
82. Binder R.J., Han D.K., and Srivastava P.K. CD91: a receptor for heat shock protein gp96. Nat Immunol 1 (2000) 151-155
83. Basu S., Binder R.J., Ramalingam T., et al. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14 (2001) 303-313
84. Hart J.P., Gunn M.D., and Pizzo S.V. A CD91-positive subset of CD11c+ blood dendritic cells: characterization of the APC that functions to enhance adaptive immune responses against CD91-targeted antigens. J Immunol 172 (2004) 70-78
85. Delneste Y., Magistrelli G., Gauchat J., et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17 (2002) 353-362
86. Wang R., Kovalchin J.T., Muhlenkamp P., et al. Exogenous heat shock protein-70 binds macrophage-lipid raft-microdomain and stimulates phagocytosis, processing and MHC-II presentation of antigens. Blood 107 4 (2006) 1636-1642
87. Suto R., and Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269 (1995) 1585-1588
88. Arnold-Schild D., Hanau D., Spehner D., et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol 162 (1999) 3757-3760
89. Binder R.J., and Srivastava P.K. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 6 (2005) 593-599
90. Arnold D., Faath S., Rammensee H., et al. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 182 (1995) 885-889
91. Castellino F., Boucher P.E., Eichelberg K., et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 191 (2000) 1957-1964
92. Cominacini L., Pasini A.F., Garbin U., et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 275 (2000) 12633-12638
93. Steinman R.M., Turley S., Mellman I., et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191 (2000) 411-416
94. Gallucci S., Lolkema M., and Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5 (1999) 1249-1255
95. Basu S., Binder R.J., Suto R., et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12 (2000) 1539-1546
96. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., and Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 7 (2000) 423-434
97. Millar D.G., Garza K.M., Odermatt B., et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med 9 (2003) 1469-1476
98. Melcher A., Todryk S., Hardwick N., et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 4 (1998) 581-587
99. Singh-Jasuja H., Scherer H.U., Hilf N., et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol 30 (2000) 2211-2215
100. Moroi Y., Mayhew M., Trcka J., et al. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci U S A 97 (2000) 3485-3490
101. Cho B.K., Palliser D., Guillen E., et al. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity 12 (2000) 263-272
102. Kuppner M.C., Gastpar R., Gelwer S., et al. The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol 31 (2001) 1602-1609
103. Qian J., Wang S., Yang J., et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res 11 (2005) 8808-8815
104. Binder R.J., Anderson K.M., Basu S., et al. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J Immunol 165 (2000) 6029-6035
105. Vabulas R.M., Braedel S., Hilf N., et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 277 (2002) 20847-20853
106. Ohashi K., Burkart V., Flohe S., and Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164 (2000) 558-561
107. Asea A., Rehli M., Kabingu E., et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 277 (2002) 15028-15034
108. Asea A., Kraeft S.K., Kurt-Jones E.A., et al. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 6 (2000) 435-442
109. Becker T., Hartl F.U., and Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol 158 (2002) 1277-1285
110. Chandawarkar R.Y., Wagh M.S., Kovalchin J.T., et al. Immune modulation with high-dose heat-shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis. Int Immunol 16 (2004) 615-624
111. Strbo N., Yamazaki K., Lee K., et al. Heat shock fusion protein gp96-Ig mediates strong CD8 CTL expansion in vivo. Am J Reprod Immunol 48 (2002) 220-225
112. Strbo N., Oizumi S., Sotosek-Tokmadzic V., et al. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity 18 (2003) 381-390
113. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20 (2002) 395-425
114. Parmiani G., Testori A., Maio M., et al. Heat shock proteins and their use as anticancer vaccines. Clin Cancer Res 10 (2004) 8142-8146
115. Tamura Y., Peng P., Liu K., et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278 (1997) 117-120
116. Baker-LePain J.C., Sarzotti M., Fields T.A., et al. GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J Exp Med 196 (2002) 1447-1459
117. Li Z., Qiao Y., Liu B., et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 11 (2005) 4460-4468
118. Liu B., DeFilippo A.M., and Li Z. Overcoming immune tolerance to cancer by heat shock protein vaccines. Mol Cancer Ther 1 (2002) 1147-1151
119. Kraybill W.G., Olenki T., Evans S.S., et al. A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models. Int J Hyperthermia 18 (2002) 253-266
120. Kraybill W.G., Olenki T., Evans S.S., et al. A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models. Int J Hyperthermia 18 (2002) 253-266
121. van der Z.J. Heating the patient: a promising approach?. Ann Oncol 13 (2002) 1173-1184
122. Hildebrandt B., Wust P., Ahlers O., et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43 (2002) 33-56
123. Ito A., Honda H., and Kobayashi T. Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression. Cancer Immunol Immunother 55 (2006) 320-328
124. Ito A., Tanaka K., Honda H., et al. Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. J Biosci Bioeng 96 (2003) 364-369
125. Zeng Y., Graner M.W., Feng H., et al. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl + murine leukemia. Int J Cancer 110 (2004) 251-259
126. Graner M.W., Zeng Y., Feng H., et al. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 52 (2003) 226-234
127. Graner M., Raymond A., Akporiaye E., et al. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol Immunother 49 (2000) 476-484
128. Janetzki S., Palla D., Rosenhauer V., et al. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 88 (2000) 232-238
129. Todryk S.M., Eaton J., Birchall L., et al. Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity. Cancer Immunol Immunother 53 (2004) 323-330
130. Casey D.G., Lysaght J., James T., et al. Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine. Immunology 110 (2003) 105-111
131. Yamazaki K., Nguyen T., and Podack E.R. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol 163 (1999) 5178-5182
132. Raez L.E., Fein S., and Podack E.R. Lung cancer immunotherapy. Clin Med Res 3 (2005) 221-228
133. Manjili M.H., Wang X.Y., Chen X., et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 171 (2003) 4054-4061
134. Ma J.H., Sui Y.F., Ye J., et al. Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo. Cancer Immunol Immunother 54 (2005) 907-914
135. Wu Y., Wan T., Zhou X., et al. Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine. Cancer Res 65 (2005) 4947-4954
136. Lewis J.J. Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci U S A 101 Suppl 2 (2004) 14653-14656
137. Belli F., Testori A., Rivoltini L., et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20 (2002) 4169-4180
138. Pilla L., Patuzzo R., Rivoltini L., et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother (2005) 1-11
139. Mazzaferro V., Coppa J., Carrabba M.G., et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9 (2003) 3235-3245
140. Younes A. A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 4 (2003) 183-185